# Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects

> **NCT01188759** · PHASE3 · WITHDRAWN · sponsor: **Pfizer**

## Conditions studied

- Aspergillosis
- Invasive Pulmonary Aspergillosis
- Neuroaspergillosis

## Interventions

- **DRUG:** Voriconazole
- **DRUG:** Anidulafungin
- **DRUG:** Voriconazole

## Key facts

- **NCT ID:** NCT01188759
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-05
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2012-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01188759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01188759, "Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01188759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*